Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01580644 | Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers | PHASE1 | COMPLETED | 12 | — | — | Jan 1, 2012 | Mar 1, 2012 | Apr 20, 2012 | 1 | Belgium |
To characterize the amount of GLPG0187 in plasma over time - pharmacokinetics (PK) - after a single oral dose of either of 2 formulations of GLPG0187 prodrug in healthy subjects
| Arm | Type | Description |
|---|---|---|
| Period 1: formulation 1 oral solution | EXPERIMENTAL | - |
| Period 2: formulation 2 capsule | EXPERIMENTAL | - |
| Period 3: Selected formulation + food | EXPERIMENTAL | - |
| Period 4: Selected formulation at higher dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GLPG0187 prodrug | DRUG | - |
Inclusion Criteria: * Healthy male, age 18-50 years * BMI between 18-30 kg/m2 Exclusion Criteria: * Any condition that might interfere with the procedures or tests in this study * Drug or alcohol abuse * Smoking